Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
about
Development of bisphosphonates.Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent mannerDirect effects of bisphosphonates on breast cancer cells.Actions of bisphosphonates in animal models of breast cancerUse of Animal Models in Understanding Cancer-induced Bone PainThe role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasisBisphosphonates induce apoptosis in human breast cancer cell linesUrokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivoCT-based handling and analysis of preclinical multimodality imaging data of bone metastases.New symmetrically esterified m-bromobenzyl non-aminobisphosphonates inhibited breast cancer growth and metastases.Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG).IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion.Automated bone volume and thickness measurements in small animal whole-body MicroCT data.An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer.Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastasesAnti-tumour activity of bisphosphonates in preclinical models of breast cancer.NCCN Task Force Report: Bone Health in Cancer Care.Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo.Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia.CD8+ T cells regulate bone tumor burden independent of osteoclast resorption.TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cellsVascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2.Hypoxia, stem cells and bone tumorPreventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.Association of the metastatic phenotype with CCN family members among breast and oral cancer cells.Endothelin-1 and osteoblastic metastasisAdjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes.Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction.Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts.Does estrogen play a role in response to adjuvant bone-targeted therapies?The SK-N-AS human neuroblastoma cell line develops osteolytic bone metastases with increased angiogenesis and COX-2 expression.A tale of mice and (wo)men: development of and insights from an "all human" animal model of breast cancer metastasis to boneEffect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastasesAmino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma
P2860
Q21195188-2FEF2226-BB12-49F7-A9D1-B302D1B668DFQ24683680-E187B23D-218B-4DC3-AC22-D972ADBD6348Q24802079-BBDE397F-A626-4CB2-B1DE-BC06F3A8456FQ24802119-2425E523-B1D4-4935-90E1-D868DE1734C6Q26785501-56D29825-51AC-486E-A8C3-D406EFF8992BQ27437809-0A46E9A7-771A-4128-ABA7-B3FC42B8408DQ28344185-BB76B142-CEE5-4E23-B0C6-066F51D9DB86Q28350698-5627F779-934F-4ECA-B236-3129B602AD17Q30661841-AA397A9E-C59D-4717-AE65-8A7F6061FE89Q33415020-22DA654C-3729-4982-B344-60031F106B6EQ33756117-D7434131-6FE1-4E5C-BB31-0DE5CA70A2C5Q33834762-25828A2E-CC9C-4EDF-99CE-D3BCF7943E34Q33898576-5904B053-3DC8-4246-B244-DC20E5E2BD74Q33952555-6A3D3ADA-1355-4BE5-B8BE-DD1497B4B7D6Q34047390-03E9F5AD-7333-4177-B5F8-D3B7E3D94DA8Q34130512-0E8434EA-437A-42D9-9420-0FF396440A93Q34561406-E6B26F61-D020-41BB-865B-FF09635E1BC8Q34613492-D6B35FA9-E76B-4A05-96B2-971156C487BDQ34617936-29A25114-F7C1-4A1D-B6BC-56BCA044FD8AQ34825844-1D16184A-2DA8-41BC-9D40-5FFEFA577D90Q35051528-4A3AB11E-8160-42AF-86D6-080DACAA6B84Q35112793-62C7D94D-D4A1-49BA-B8BB-6316633C9EC8Q35169027-50E76D96-2286-4C8F-93B3-78EB8140FEB8Q35289963-D9AC06F1-46A2-4982-B352-F16911916116Q35549238-61E62C18-13A3-4CF0-887D-EBE56C5A5F8CQ35590612-C6CE1D03-458D-479D-B9B3-3476CF25B98FQ35633001-2D623541-ECD9-4C7D-8819-5D56D42910CAQ35976870-0A4EE573-B5CA-4A12-95EA-19195751D5E2Q36216730-EC80DE33-0B3F-4188-A0D9-6216A9123B08Q36476085-D855C459-555B-415C-BBA0-9DDC0E9983B8Q36491357-BB483C2F-1D64-4042-AE73-6D7A06199EC5Q36491378-106FA31B-6078-4BD4-90AD-33D6D86E6C3AQ36491529-65D6E109-DBFF-44C2-B6E3-04AA52699F18Q36492336-4B94FB76-605A-4540-98AD-0FA7E4B5C400Q36519704-726722D1-15C2-4821-911F-0D6BA6FEAE53Q36609555-226CE733-6A2F-48C6-8BE5-9C0392FA6FB7Q36644394-5ECD9C8B-84FD-4F1B-B11E-7F845D4FFAEFQ36963360-BC230529-AAA1-436D-8A52-CCE3ACE862AEQ37066448-18E004CC-0B52-40AA-B628-CDCC6FEF7A0DQ37106218-092399F0-3481-4620-A4B2-807BC81F4A5E
P2860
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Bisphosphonate risedronate red ...... r burden in bone in nude mice.
@en
type
label
Bisphosphonate risedronate red ...... r burden in bone in nude mice.
@en
prefLabel
Bisphosphonate risedronate red ...... r burden in bone in nude mice.
@en
P2093
P1433
P1476
Bisphosphonate risedronate red ...... r burden in bone in nude mice.
@en
P2093
P304
P407
P577
1995-08-01T00:00:00Z